The value of serum TRAP1 in diagnosing small cell lung cancer and tumor immunity

作者：Liming Tan, Shi‐Peng Ke, Xu Li, Tanglin Ouyang, Li‐Qing Yu, Jiali Yu, Yakun Wang, Qijun Yang, Xiaohang Li, Yu Xia, Hua Li, Xiao-Yan Hu · 发表于：Experimental Biology and Medicine · 年份：2023 · DOI：10.1177/15353702221142614 · 被引用次数：8 · 研究领域：Lung Cancer Research Studies、Galectins and Cancer Biology、Peptidase Inhibition and Analysis

This study set out to investigate the clinical significance of serum tumor necrosis factor receptor-associated protein 1 (TRAP1) in diagnosing small cell lung cancer (SCLC) with different clinical stages, and to compare the diagnostic efficiency with neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). Besides, to analyze the role of serum TRAP1 in tumor immunity. A total of 91 patients with SCLC, 99 patients with non–small cell lung cancer (NSCLC), 102 patients with pulmonary nodules (PN), and 75 healthy people were included. The concentrations of serum TRAP1 was detected by enzyme-linked immunosorbent assay (ELISA). NSE, CEA, and CA19-9 were detected by chemiluminescence. The results showed that level of TRAP1 in Group SCLC was lower than other three groups ( P < 0.01), whereas NSE in SCLC was significantly higher than the others ( P < 0.01), and the levels of CEA and CA19-9 were higher than healthy people and PN patients ( P < 0.01). There was a significant difference in TRAP1 levels between patients with limited-stage disease SCLC (LD-SCLC) and extensive-stage disease SCLC (ED-SCLC) ( P < 0.0001). The sensitivity and specificity of TRAP1 in diagnosing LD-SCLC were 0.964 and 0.560, respectively, and the area under the curve (AUC) was 0.819. The sensitivity and specificity in diagnosing ED-SCLC were 0.810 and 0.868, respectively, and the AUC was 0.933, which showed high diagnostic value. The AUC of these two group...